Network meta-analysis of pneumonitis and interstitial lung disease associated with antibody-drug conjugates in the treatment of breast cancer

WANG Xiaohan; CHEN Wei; YANG Fang; CAO Keming; WANG Jingxin; XUE Wenxin

doi:10.6039/j.issn.1001-0408.2026.10.23

您当前的位置：

首页 >

文章列表页 >

Network meta-analysis of pneumonitis and interstitial lung disease associated with antibody-drug conjugates in the treatment of breast cancer

更新时间：2026-05-26

- Network meta-analysis of pneumonitis and interstitial lung disease associated with antibody-drug conjugates in the treatment of breast cancer
- ZHONGGUO YAOFANG Vol. 37, Issue 10, Pages: 1370-1375(2026)
- 作者机构：
  
  1.华北理工大学药学院，唐山　063210
  2.应急总医院药学部，北京　100028
  3.应急总医院东院区综合门诊，北京　100016
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.10.23
  CLC： R737.9;R969.3
- Received：12 January 2026，
  
  Revised：2026-05-09，
  
  Accepted：09 May 2026，
  
  Published：30 May 2026
- 稿件说明：
移动端阅览
王晓函,陈威,杨芳,等.抗体偶联药物治疗乳腺癌后致肺炎和间质性肺病的网状Meta分析 ^Δ[J].中国药房,2026,37(10):1370-1375. DOI: 10.6039/j.issn.1001-0408.2026.10.23.

WANG Xiaohan,CHEN Wei,YANG Fang,et al.Network meta-analysis of pneumonitis and interstitial lung disease associated with antibody-drug conjugates in the treatment of breast cancer[J].ZHONGGUO YAOFANG,2026,37(10):1370-1375.
王晓函,陈威,杨芳,等.抗体偶联药物治疗乳腺癌后致肺炎和间质性肺病的网状Meta分析 ^Δ[J].中国药房,2026,37(10):1370-1375. DOI: 10.6039/j.issn.1001-0408.2026.10.23. DOI：

WANG Xiaohan,CHEN Wei,YANG Fang,et al.Network meta-analysis of pneumonitis and interstitial lung disease associated with antibody-drug conjugates in the treatment of breast cancer[J].ZHONGGUO YAOFANG,2026,37(10):1370-1375. DOI： 10.6039/j.issn.1001-0408.2026.10.23.

摘要

目的

比较不同抗体偶联药物（ADC）治疗乳腺癌后致肺炎和间质性肺病（ILD）的发生风险。

方法

检索中国知网、维普网、PubMed、Embase等中英文数据库和ClinicalTrials.gov，收集ADC[恩美曲妥珠单抗（T-DM1）、德曲妥珠单抗（T-DXd）、戈沙妥珠单抗（SG）、德达博妥单抗（Dato-DXd）、瑞康曲妥珠单抗（SHR-A1811）、ARX788、T-Duo]治疗乳腺癌后发生肺炎和ILD的随机对照试验（RCT），检索时间为建库至2025年6月15日。筛选文献、提取数据、评价文献质量后，采用Stata 17.0软件进行网状Meta分析，并对各干预措施的累积排序曲线下面积（SUCRA）进行排序。

结果

共纳入19项RCT，共计10 556例患者。ARX788、T-DXd的总体肺炎发生率显著高于T-DM1、T-DM1 plus TPC（T-DM1联合帕妥珠单抗或阿替利珠单抗）、TPC（常规治疗）和SG（

＜0.05），ARX788、T-DXd的1～2级肺炎发生率显著高于T-DM1、T-DM1 plus TPC和TPC（

＜0.05），上述2个指标SUCRA排序前2位的均为ARX788、T-Duo。T-DXd、T-DM1的≥3级肺炎发生率显著高于SG（

＜0.05），SUCRA排序前2位的为T-Duo、Dato-DXd。ARX788的总体ILD发生率显著高于T-DM1、SHR-A1811、TPC和SG（

＜0.05），1～2级ILD发生率显著高于T-DM1、SHR-A1811和TPC（

＜0.05），≥3级ILD发生率显著高于TPC（

＜0.05），上述3个指标SUCRA排序前2位的均为ARX788、T-DXd联合帕妥珠单抗。

结论

相比于其他ADC，ARX788和T-Duo治疗乳腺癌后患者的肺炎和ILD发生风险较高。

Abstract

OBJECTIVE

To compare the risk of pneumonitis and interstitial lung disease （ILD） associated with different antibody-drug conjugates （ADC） in the treatment of breast cancer.

METHODS

CNKI， VIP， PubMed， Embase and other Chinese and English databases， and ClinicalTrials.gov were searched from the inception to June 15， 2025. Randomized controlled trials （RCT） about pneumonitis and ILD associated with ADC （T-DM1， T-DXd， SG， Dato-DXd， SHR-A1811，ARX788， and T-Duo） in the treatment of breast cancer were included. After literature screening， data extraction， and quality assessment， a network meta-analysis was conducted using Stata 17.0 software， and the surface under the cumulative ranking curve（SUCRA） of all interventions were ranked.

RESULTS

A total of 19 RCTs involving 10 556 patients were included. The overall incidence of

pneumonitis with ARX788 and T-DXd was significantly higher than that with T-DM1， T-DM1 plus TPC（T-DM1combined with pertuzumab or atezolizumab）， TPC（treatment of primary care）， and SG （

＜0.05）， for grade 1-2 pneumonitis， ARX788 and T-DXd showed significantly higher incidence than T-DM1， T-DM1 plus TPC， and TPC （

＜0.05）. For both indicators， ARX788 and T-Duo were ranked as the top two by SUCRA. For the incidence of grade ≥3 pneumonitis， T-DXd and T-DM1 were significantly higher than SG （

＜0.05）， T-Duo and Dato-DXd were ranked as the top two by SUCRA. For overall incidence of ILD， ARX788 was significantly higher than T-DM1， SHR-A1811， TPC， and SG （

＜0.05）， for the incidence of grade 1-2 ILD， ARX788 was significantly higher than T-DM1， SHR-A1811， and TPC （

＜0.05）， for the incidence of grade ≥3 ILD， ARX788 was significantly higher than TPC （

＜0.05）. For three indicators above， ARX788 and T-DXd combined with pertuzumab were ranked as the top two by SUCRA.

CONCLUSIONS

Compared with other ADCs， ARX788 and T-Duo are associated with a higher risk of pneumonitis and ILD in patients with breast cancer.

关键词

Keywords

references

BRAY F ， LAVERSANNE M ， SUNG H ， et al . Global cancer statistics 2022：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2024 ， 74 （ 3 ）： 229 - 263 .

CHAU C H ， STEEG P S ， FIGG W D . Antibody-drug conjugates for cancer [J ] . Lancet ， 2019 ， 394 （ 10200 ）： 793 - 804 .

MODI S N ， SAURA C ， YAMASHITA T ， et al . Trastuzumab deruxtecan in previously treated HER2-positive breast cancer [J ] . N Engl J Med ， 2020 ， 382 （ 7 ）： 610 - 621 .

MODI S ， JACOT W ， YAMASHITA T ， et al . Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer [J ] . N Engl J Med ， 2022 ， 387 （ 1 ）： 9 - 20 .

CORTÉS J ， KIM S B ， CHUNG W P ， et al . Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer [J ] . N Engl J Med ， 2022 ， 386 （ 12 ）： 1143 - 1154 .

POWELL C A ， MODI S ， IWATA H ， et al . Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies [J ] . ESMO Open ， 2022 ， 7 （ 4 ）： 100554 .

QURESHI Z ， ALTAF F ， JAMIL A ， et al . Safety and efficacy of trastuzumab deruxtecan for metastatic HER2+ and HER2-low breast cancer：an updated systematic review and meta-analysis of clinical trials [J ] . J Clin Oncol ， 2024 ， 47 （ 11 ）： 535 - 541 .

刘津池，刘畅，华成舸 . 随机对照试验偏倚风险评价工具RoB2：2019修订版解读 [J ] . 中国循证医学杂志， 2021 ， 21 （ 6 ）： 737 - 744 .

NIKOLAKOPOULOU A ， HIGGINS J P T ， PAPAKONSTANTINOU T ， et al . CINeMA：an approach for assessing confidence in the results of a network meta-analysis [J ] . PLoS Med ， 2020 ， 17 （ 4 ）： e1003082 .

MBUAGBAW L ， ROCHWERG B ， JAESCHKE R ， et al . Approaches to interpreting and choosing the best treatments in network meta-analyses [J ] . Syst Rev ， 2017 ， 6 （ 1 ）： 79 .

HURVITZ S A ， DIRIX L ， KOCSIS J ， et al . Phase Ⅱ randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer [J ] . J Clin Oncol ， 2013 ， 31 （ 9 ）： 1157 - 1163 .

KROP I E ， KIM S B ， MARTIN A G ， et al . Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer（TH3RESA）：final overall survival results from a randomised open-label phase 3 trial [J ] . Lancet Oncol ， 2017 ， 18 （ 6 ）： 743 - 754 .

HURVITZ S A ， MARTIN M ， SYMMANS W F ， et al . Neoadjuvant trastuzumab，pertuzumab，and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer（KRISTINE）：a randomised，open-label，multicentre，phase 3 trial [J ] . Lancet Oncol ， 2018 ， 19 （ 1 ）： 115 - 126 .

VON MINCKWITZ G ， HUANG C S ， MANO M S ， et al . Trastuzumab emtansine for residual invasive HER2-positive breast cancer [J ] . N Engl J Med ， 2019 ， 380 （ 7 ）： 617 - 628 .

EMENS L A ， ESTEVA F J ， BERESFORD M ， et al . Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated，HER2-positive advanced breast cancer（KATE2）：a phase 2，multicentre，randomised，double-blind trial [J ] . Lancet Oncol ， 2020 ， 21 （ 10 ）： 1283 - 1295 .

TOLANEY S M ， TAYOB N ， DANG C ， et al . Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage Ⅰ HER2-positive breast cancer（ATEMPT）：a randomized clinical trial [J ] . J Clin Oncol ， 2021 ， 39 （ 21 ）： 2375 - 2385

KROP I E ， IM S A ， BARRIOS C ， et al . Trastuzumab emtansine plus pertuzumab versus taxane plus trastuzumab plus pertuzumab after anthracycline for high-risk human epidermal growth factor receptor 2-positive early breast cancer：the phase Ⅲ KAITLIN study [J ] . J Clin Oncol ， 2022 ， 40 （ 5 ）： 438 - 448 .

RUGO H S ， BARDIA A ， MARMÉ F ， et al . Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer [J ] . J Clin Oncol ， 2022 ， 40 （ 29 ）： 3365 - 3376 .

ANDRÉ F ， HEE PARK Y ， KIM S B ， et al . Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer（DESTINY-Breast02）：a randomised，open-label，multicentre，phase 3 trial [J ] . Lancet ， 2023 ， 401 （ 10390 ）： 1773 - 1785 .

HURVITZ S A ， HEGG R ， CHUNG W P ， et al . Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer：updated results from DESTINY-Breast03，a randomised，open-label，phase 3 trial [J ] . Lancet ， 2023 ， 401 （ 10371 ）： 105 - 117 .

WANG X J ， LI W ， YIN Y M ， et al . Primary results of ELAINA：a randomized，multicenter，open-label，phase Ⅲ study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy [J ] . Transl Breast Cancer Res ， 2023 ， 4 ： 3 .

BARDIA A ， JHAVERI K ， IM S A ， et al . Datopotamab deruxtecan versus chemotherapy in previously treated inope-rable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer：primary results from TROPION-breast01 [J ] . J Clin Oncol ， 2025 ， 43 （ 3 ）： 285 - 296 .

HU X C ， ZHANG Q Y ， WANG L P ， et al . ACE-Breast-02：a randomized phase Ⅲ trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer [J ] . Signal Transduct Target Ther ， 2025 ， 10 （ 1 ）： 56 .

TURNER N ， SAURA C ， AFTIMOS P ， et al . Trastuzumab duocarmazine in pretreated human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer：an open-label，randomized，phase Ⅲ trial（TULIP） [J ] . J Clin Oncol ， 2025 ， 43 （ 5 ）： 513 - 523 .

ANDRE F ， HAMILTON E P ， LOI S ， et al . DESTINY-Breast07：dose-expansion interim analysis of T-DXd monotherapy and T-DXd+pertuzumab in patients with previously untreated HER2+mBC [J ] . J Clin Oncol ， 2024 ， 42 （ Suppl. 16 ）： 1009 .

BARDIA A ， HU X C ， DENT R ， et al . Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer [J ] . N Engl J Med ， 2024 ， 391 （ 22 ）： 2110 - 2122 .

LI J J ， WANG Z H ， CHEN L ， et al . Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer：a randomized，open-label，phase Ⅱ trial [J ] . Ann Oncol ， 2025 ， 36 （ 6 ）： 651 - 659 .

JI C C ， LI F ， YUAN Y ， et al . Novel anti-HER2 antibody-drug conjugates versus T-DM1 for HER2-positive metastatic breast cancer after tyrosine kinase inhibitors treatment [J ] . Oncologist ， 2023 ， 28 （ 10 ）： e859 - e866 .

GOULD B J ， BOROWITZ M J ， GROVES E S ， et al . Phase Ⅰ study of an anti-breast cancer immunotoxin by continuous infusion：report of a targeted toxic effect not predicted by animal studies [J ] . JNCI J Natl Cancer Inst ， 1989 ， 81 （ 10 ）： 775 - 781 .

TARANTINO P ， TOLANEY S M . Detecting and mana-ging T-DXd-related interstitial lung disease：the five “S” rules [J ] . JCO Oncol Pract ， 2023 ， 19 （ 8 ）： 526 - 527 .

NAKADA T ， SUGIHARA K ， JIKOH T ， et al . The latest research and development into the antibody-drug conjugate，[fam-] trastuzumab deruxtecan（DS-8201a），for HER2 cancer therapy [J ] . Chem Pharm Bull ， 2019 ， 67 （ 3 ）： 173 - 185 .

GUPTA A ， DRAGO J Z ， CHANDARLAPATY S . ADCs or：how I learned to stop worrying and love chemotherapy [J ] . Cancer Discov ， 2023 ， 13 （ 4 ）： 817 - 818 .

BAROK M ， JOENSUU H ， ISOLA J . Trastuzumab emtansine：mechanisms of action and drug resistance [J ] . Breast Cancer Res ， 2014 ， 16 （ 2 ）： 209 .

JUNUTULA J R ， RAAB H ， CLARK S ， et al . Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index [J ] . Nat Biotechnol ， 2008 ， 26 （ 8 ）： 925 - 932 .

GOLDENBERG D M ， SHARKEY R M . Sacituzumab govitecan，a novel，third-generation，antibody-drug conjugate（ADC）for cancer therapy [J ] . Expert Opin Biol Ther ， 2020 ， 20 （ 8 ）： 871 - 885 .

ROSENBERG J E ， O’DONNELL P H ， BALAR A V ， et al . Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy [J ] . J Clin Oncol ， 2019 ， 37 （ 29 ）： 2592 - 2600 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Pharmacoeconomic evaluation of culmerciclib combined with fulvestrant in the second-line treatment of HR+/HER2－ locally advanced or metastatic breast cancer

Study on the effect and mechanism of modified Yanghe decoction on bone destruction in rats with breast cancer bone metastasis

Research progress on the mechanism of traditional Chinese medicine regulating metabolic reprogramming to improve breast cancer

Research progress on antibody-drug conjugates in the treatment of triple-negative breast cancer

1例乳腺癌合并静脉血栓栓塞患者的抗凝方案优化

Related Author

LIU Ran

GAO Shengnan

LI Congxin

ZHANG Yuxi

ZHANG Ranran

WANG Yue

LIU Ziyi

LIU Guoqiang

Related Institution

Dept. of Pharmacy， Hebei Medical University Third Hospital

School of Graduate， Hebei Medical University

Hebei Society for Integrated Drug and Health Technology Assessment

Dept. of Oncology， Wuhan Hospital of Traditional Chinese Medicine

Dept. of Orthopedics and Traumatology， Wuhan Hospital of Traditional Chinese Medicine

⁰